The most recent studies indicate that with newer conventional heart failure treatment consisting of diuretics, ACE inhibitors and beta blockers, the survival rate is very high at 98% or better, and almost all<unk>  patients improve with treatment. In the United States, over 50% of<unk>  patients experience complete recovery of heart function (EF 55% or greater). Almost all recovered patients are eventually able to discontinue medications with no resulting relapse and have normal life expectancy. It is a misconception that hope for recovery depends upon improvement or recovery within the first six to 12 months of diagnosis. Many women continue to improve or recover even years after diagnosis with continued medicinal treatment. Once fully recovered, if there is no subsequent pregnancy, the possibility of relapse or recurrence of heart failure is minimal. Subsequent pregnancy should be avoided when left ventricular function has not recovered and the EF is lower than 55%. However, many women who have fully recovered from<unk>  have gone on to have successful subsequent pregnancies. A significant study reports that the risk for recurrence of heart failure in recovered<unk>  patients as a result of subsequent pregnancy is approximately 21% or better. The chance of relapse may be even smaller for those with normal contractile reserve as demonstrated by stress echocardiography. In any subsequent pregnancy, careful monitoring is necessary. Where relapse occurs, conventional treatment should be resumed, including hydralazine with nitrates plus beta-blockers during pregnancy, or ACE-inhibitors plus beta-blockers following pregnancy.
Peripartum cardiomyopathy
Takotsubo cardiomyopathy
Arrhythmogenic cardiomyopathy
Aicardi syndrome
Sudden arrhythmic death syndrome
Uremic pericarditis
Alcoholic cardiomyopathy
Toxic anterior segment syndrome